Behzad Najafian
Overview
Explore the profile of Behzad Najafian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
2354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Paueksakon P, Najafian B, Akilesh S, Alpers C, Fogo A
Am J Kidney Dis
. 2025 Feb;
85(3):e1-e2.
PMID: 39986702
No abstract available.
2.
Newman J, Hughes C, Bloch K, Deveaux K, Allen S, Truong T, et al.
Emerg Infect Dis
. 2025 Feb;
31(2):350-354.
PMID: 39983692
A previously healthy 26-year-old woman in middle Tennessee, USA, experienced a first trimester pregnancy loss after multiple tick bites. Histopathology, 16S rRNA sequencing, and electron microscopy examination of the products...
3.
Campbell M, Sanchez-Contreras M, Sibley B, Keiser P, Ruiz Sanchez C, Mann C, et al.
bioRxiv
. 2024 Dec;
PMID: 39651288
Whether and how podocytes depend on mitochondria across their long post-mitotic lifespan is yet unclear. With limited cell numbers and broad kidney distribution, isolation of podocyte mitochondria typically requires first...
4.
Ebrahimi N, Najafian B, Chen Wongworawat Y, Norouzi S, Abdipour A
J Investig Med High Impact Case Rep
. 2024 Sep;
12:23247096241281612.
PMID: 39315468
Anti-tubular basement membrane (anti-TBM) antibody nephritis is a rare type of tubulointerstitial nephritis associated with progressive decline in kidney function. It is characterized histopathologically by tubular atrophy and dilation, interstitial...
5.
Shankland S, Najafian B, Wessely O
Kidney Int
. 2024 May;
105(6):1153-1156.
PMID: 38777397
No abstract available.
6.
Chang F, Hsu T, Hung S, Sung S, Yu W, Niu D, et al.
medRxiv
. 2024 Jan;
PMID: 38168318
Background: While cardiovascular complications are the most common cause of mortality in Fabry disease, the relationship between globotriaosylceramide (GL-3) accumulation, the hallmark of Fabry cardiomyopathy, and cardiac hypertrophy has not...
7.
Paueksakon P, Najafian B, Alpers C, Fogo A
Am J Kidney Dis
. 2023 Dec;
83(1):e1-e2.
PMID: 38129071
No abstract available.
8.
Smerkous D, Mauer M, Tondel C, Svarstad E, Gubler M, Nelson R, et al.
Kidney Int
. 2023 Sep;
105(1):165-176.
PMID: 37774924
Podocyte injury plays a key role in pathogenesis of many kidney diseases with increased podocyte foot process width (FPW), an important measure of podocyte injury. Unfortunately, there is no consensus...
9.
Braun F, Abed A, Sellung D, Rogg M, Woidy M, Eikrem O, et al.
J Clin Invest
. 2023 Apr;
133(11).
PMID: 37014703
Current therapies for Fabry disease are based on reversing intracellular accumulation of globotriaosylceramide (Gb3) by enzyme replacement therapy (ERT) or chaperone-mediated stabilization of the defective enzyme, thereby alleviating lysosomal dysfunction....
10.
Deegan P, Goker-Alpan O, Geberhiwot T, Hopkin R, Lukina E, Tylki-Szymanska A, et al.
Mol Genet Metab
. 2022 Dec;
138(2):106963.
PMID: 36481125
Venglustat inhibits the enzymatic conversion of ceramide to glucosylceramide, reducing available substrate for the synthesis of more complex glycosphingolipids. It offers a potential new approach to the treatment of patients...